ImmunoPrecise jumps after AI peptides beat semaglutide in lab tests

Mindwalk Holdings

12/06/2025 13:27

** Shares of biotech firm ImmunoPrecise Antibodies IPA.O rise 17.5% to $70 premarket

** IPA says it has used AI to design new peptides that are as effective as or better than semaglutide, a popular drug for treating diabetes, in lab test

** Two of their five engineered peptides matched or exceeded semaglutide's performance in receptor activation tests

** Co's proprietary tech, called HYFT and LENSai, uses mathematical patterns to design peptides that are stable, effective and biologically active

** IPA says it is planning to test the peptides in animal models and explore different ways of delivering them to patients, such as injections or skin patches

** Semaglutide, sold by Danish drugmaker Novo Nordisk NOVOb.CO, is the active ingredient in Ozempic and Wegovy to treat diabetes and obesity

** As of last close, IPA's stock was up 45.8% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))